CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction that occurred on Thursday, January 2nd. The ...

Hamilton James C, Chief of Discovery/Trans Medicine at Arrowhead Pharmaceuticals ... The transaction comes as the stock has declined over 50% in the past year, with InvestingPro data showing ...

State Street Corp raised its stake in Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $ ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), which has seen its stock decline over 50% in the past year according to InvestingPro data, recently reported that Patrick O'Brien, the company's ...

December 23, 2024--Arrowhead Pharmaceuticals ... to receive up to 44,350 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and PASADENA ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals (IONS – Research ...

The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and PASADENA, Calif., ...

In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies Arrowhead ...

Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.